ISA to Present at the 4th Annual Virtual H.C. Wainwright HBV Conference on October 25th

First Patient with Chronic Hepatitis B Dosed with ISA104 in First-in-Human Phase 1 Study

The combination of ISA101b and Libtayo® shows promising results in patients whose head and neck cancer progressed on anti-PD1 therapy

ISA Pharmaceuticals to Attend and Present at Upcoming Scientific and Business Conferences

ISA Pharmaceuticals and Cancer Focus Fund Announce $5 Million Investment to Support First-in-Human Trial of ISA’s Novel Immunotherapy ISA103 in Uveal Melanoma

ISA Completes Enrolment in Randomized Double Blind Phase 2 Clinical Trial of ISA101b in HPV16 induced Oropharyngeal Cancer

Professor Melief to receive 2022 SITC Pedro J. Romero Award

ISA Pharmaceuticals’ Chief Scientific Officer Prof. Dr. Melief Awarded Fellowship at the Society for Immunotherapy of Cancer

ISA to Present at Business Conferences in May 2022

ISA Pharmaceuticals announces the start of clinical trial using its novel AMPLIVANT® technology